Technical Analysis for ZYME - Zymeworks Inc.

Grade Last Price % Change Price Change
F 36.31 -3.10% -1.16
ZYME closed down 3.1 percent on Friday, February 26, 2021, on 73 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: Mar 2
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical ZYME trend table...

Date Alert Name Type % Chg
Stochastic Reached Oversold Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
200 DMA Resistance Bearish -3.10%
Fell Below 20 DMA Bearish -3.10%
Multiple of Ten Bearish Other -3.10%
Fell Below 200 DMA Bearish -9.90%
180 Bearish Setup Bearish Swing Setup -9.90%
20 DMA Support Bullish -11.55%
Crossed Above 200 DMA Bullish -11.55%
Older End-of-Day Signals for ZYME ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% 3 days ago
Down 2 % 3 days ago
Down 1% 3 days ago
Up 2% 3 days ago
Up 1% 3 days ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Zymeworks Inc. Description

Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company's ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company's platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins. The Company's lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immunology Immune System Cancers Monoclonal Antibodies Cancer Immunotherapy Antibody Her2 Toxins Sutro Biopharma Glycoproteins Biological Systems Bispecific Monoclonal Antibody Protein Engineering

Is ZYME a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 59.03
52 Week Low 20.33
Average Volume 519,628
200-Day Moving Average 40.68
50-Day Moving Average 46.24
20-Day Moving Average 39.49
10-Day Moving Average 40.16
Average True Range 2.61
ADX 20.4
+DI 17.12
-DI 34.94
Chandelier Exit (Long, 3 ATRs ) 39.62
Chandelier Exit (Short, 3 ATRs ) 40.34
Upper Bollinger Band 43.99
Lower Bollinger Band 34.99
Percent B (%b) 0.15
BandWidth 22.78
MACD Line -1.99
MACD Signal Line -2.01
MACD Histogram 0.011
Fundamentals Value
Market Cap 1.66 Billion
Num Shares 45.6 Million
EPS -1.63
Price-to-Earnings (P/E) Ratio -22.28
Price-to-Sales 105.44
Price-to-Book 5.79
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 39.74
Resistance 3 (R3) 39.97 39.05 39.17
Resistance 2 (R2) 39.05 38.18 38.94 38.98
Resistance 1 (R1) 37.68 37.64 37.23 37.45 38.79
Pivot Point 36.77 36.77 36.54 36.65 36.77
Support 1 (S1) 35.40 35.90 34.94 35.17 33.83
Support 2 (S2) 34.48 35.36 34.37 33.64
Support 3 (S3) 33.11 34.48 33.45
Support 4 (S4) 32.88